Enzalutamide - CISMeF

Preferred Label : Enzalutamide;

NCIt synonyms : Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-; Selective Androgen Receptor Modulator MDV3100;

NCIt definition : An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.;

UNII : 93T0T9GKNU;

InChIKey : WXCXUHSOUPDCQV-UHFFFAOYSA-N;

CAS number : 915087-33-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 915087-33-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Xtandi;

Molecule name : MDV3100; ASP9785;

Chemical formula : C21H16F4N4O2S;

Codes from synonyms : 189;

Details

Origin ID

C71744;

UMLS CUI

C3496793;

Automatic exact mappings (from CISMeF team)
- Enzalutamide [ICD-11 Extension code]
- enzalutamide [ATC Code]
CISMeF manual mappings
- Enzalutamide (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-n-methyl- [Substance BNPC]
- enzalutamide [MeSH concept]
- enzalutamide [MeSH Supplementary Concept]
- enzalutamide [International Nonproprietary Name]
See also inter- (CISMeF)
- Product containing enzalutamide (medicinal product) [SNOMED CT concept]
- Xtandi [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Enzalutamide (substance) [SNOMED CT concept]
- Product containing enzalutamide (medicinal product) [SNOMED CT concept]
- benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-n-methyl- [Substance BNPC]
- enzalutamide [MeSH concept]
- enzalutamide [ATC Code]
- enzalutamide [International Nonproprietary Name]
- enzalutamide [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
- Operational Ontology for Radiation Oncology Prostate Cancer Terminology [NCIt concept]
has_target
- Androgen Receptor [NCIt concept]
is_component_of_chemotherapy_regimen
- Degarelix/Enzalutamide Regimen [NCIt concept]
- Enzalutamide Regimen [NCIt concept]
- Enzalutamide/Goserelin Regimen [NCIt concept]
- Enzalutamide/Leuprolide Regimen [NCIt concept]
- Enzalutamide/Talazoparib Regimen [NCIt concept]
- Enzalutamide/Triptorelin Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients